查詢結果分析
相關文獻
- Uterine Myoma after Cessation of Gonadotropin-Releasing Hormone Agonist: Ultrasound and Histopathologic Findings
- 婦女最常見的子宮肌瘤
- 子宮肌瘤與肌腺瘤
- 子宮肌瘤的內科療法--GnRHa
- 子宮肌瘤的組織發生論和臨床內分泌學
- A Huge 6.2 Kilogram Uterine Myoma Coinciding with Omental Leiomyosarcoma: Case Report
- 子宮肌瘤切除臨床路徑探討
- 性腺激素釋放類似劑(GnRHa)在子宮肌瘤的應用
- 子宮肌瘤病例討論
- Cytogenetic Study of Uterine Leiomyomas
頁籤選單縮合
題 名 | 子宮肌瘤治療新藥簡介=A Novel Medical Therapy for Treatment of Uterine Fibroids |
---|---|
作 者 | 童俊欽; 李建瑩; | 書刊名 | 藥學雜誌 |
卷 期 | 32:3=128 2016.09[民105.09] |
頁 次 | 頁71-73 |
分類號 | 418.276 |
關鍵詞 | 子宮肌瘤; Ulipristal acetate; |
語 文 | 中文(Chinese) |
中文摘要 | 子宮肌瘤是育齡婦女最常見的良性子宮腫瘤。雖然大多數婦女是無症狀,然而纖 維瘤根據其類型和位置,各有不同的症狀和生活品質影響。迄今為止,還沒有藥物可 以完全消除肌瘤。Ulipristal acetate 為一種具口服活性的合成選擇性黃體素受體調節 劑,其特性是黃體素受體拮抗劑的作用以減少平滑肌瘤細胞的增生和誘導細胞凋亡。 在2012年因其藥理和藥物代謝動力學特性,它被准許在歐洲作為子宮肌瘤的術前治療 藥物,其療效和良好的耐受性使其成為在子宮肌瘤管理上的一個新的重要工具。 |
英文摘要 | Uterine fibroids are the most common benign uterine tumors in women of reproductive age. Although most women are asymptomatic, fibroids, according to their type and location, can cause several symptoms and impact quality of life. To date, no medical treatment is able to eliminate fibroids. Ulipristal acetate is an orally active synthetic selective progesterone receptor modulator characterized by a tissue-specific progesterone antagonist effect that reduces the proliferation of leiomyoma cells and induces apoptosis. It was licensed in Europe for preoperative fibroid treatment in 2012. Its pharmacological and pharmacodynamic characteristics, its efficacy and good tolerance make Ulipristal acetate a new important tool in the management of uterine fibroids. |
本系統中英文摘要資訊取自各篇刊載內容。